The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected Pregnant women

The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand.
Antiviral therapy (Impact Factor: 3.02). 01/2009; 14(3):443-50.
Source: PubMed


Pregnancy affects the pharmacokinetics of most protease inhibitors. Saquinavir, when administered in a tablet formulation, has not been studied extensively in this setting.
A pharmacokinetic, prospective, multicentre trial of HIV type-1-infected pregnant women treated with saquinavir (500 mg tablets) boosted with ritonavir at a dose of 1,000/100 mg twice daily plus a nucleoside backbone was conducted. Pharmacokinetic curves were recorded for 12 h in the second trimester (week 20 +/-2), the third trimester (week 33 +/-2) and post-partum (weeks 4-6). Blood was sampled pre-dosing and at 1, 2, 3, 4, 6, 8, 10 and 12 h post-dosing. Pharmacokinetic parameters were calculated using WinNonlin software version 4.1.
A total of 37 women were included in the analysis. Mean (+/-sd) values for saquinavir area under the curve (AUC(0-12h)) were 23.47 h*mg/l (11.92) at week 20 (n=16), 23.65 h*mg/l (9.07) at week 33 (n=31) and 25.00 h*mg/l (11.81) post-partum (n=9). There was no significant difference in the saquinavir AUC(0-12h) when comparing the data during pregnancy and post-partum. Subtherapeutic plasma concentrations of saquinavir (defined as <0.10 mg/l) were not observed throughout the study. No major safety concerns were noted.
Saquinavir exposure in the new tablet formulation generates adequate saquinavir concentrations throughout the course of pregnancy and is safe to use; therefore, no dose adjustment during pregnancy is needed.

Download full-text


Available from: José Moltó,
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the presented study was to look for a relationship between physicochemical parameters of selected drugs and the value of between-subject variability of area under the curve (AUCBSV). The analysis was performed for a group of 100 drugs prescribed in different disease entities in humans. At first, a direct correlation between 52 physicochemical parameters and AUCBSV was determined. In the next step, physicochemical parameters of the drugs calculated in silico were divided into quintile groups and a search for the correlation between the AUCBSV values for individual parameters in each quintile group and the number of the quintile was conducted. Only in case of 5 of the 52 parameters analyzed (partition coefficient octanol/water - XLogP, ionization potential - IP, globularity - Glob, polarizability - α, and polar surface area - PSA), it was possible to create an arithmetic expression $ [(X\log P + {\text{IP}} + {\text{Glob}})^{{{\text{Log}}\alpha}} - {\text{PSA}}] $ , for which the correlation with AUCBSV value was statistically significant (P < 0.05). Results of this study indicate that XLogP, α, IP, Glob, and PSA are a group of physicochemical parameters related to AUCBSV.
    Medicinal Chemistry Research 04/2012; 22(4). DOI:10.1007/s00044-012-0187-7 · 1.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: HIV-2 contributes approximately a third to the prevalence of HIV in West Africa and is present in significant amounts in several low-income countries outside of West Africa with historical ties to Portugal. It complicates HIV diagnosis, requiring more expensive and technically demanding testing algorithms. Natural polymorphisms and patterns in the development of resistance to antiretrovirals are reviewed, along with their implications for antiretroviral therapy. Nonnucleoside reverse transcriptase inhibitors, crucial in standard first-line regimens for HIV-1 in many low-income settings, have no effect on HIV-2. Nucleoside analogues alone are not sufficiently potent enough to achieve durable virologic control. Some protease inhibitors, in particular those without ritonavir boosting, are not sufficiently effective against HIV-2. Following review of the available evidence and taking the structure and challenges of antiretroviral care in West Africa into consideration, the authors make recommendations and highlight the needs of special populations.
    AIDS research and treatment 02/2011; 2011(6):463704. DOI:10.1155/2011/463704
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Few data are available describing atazanavir exposure during pregnancy, especially when used in combination with tenofovir, whose coadministration with atazanavir results in decreased atazanavir exposure. International Maternal Pediatric Adolescent AIDS Clinical Trials 1026 s is an ongoing, prospective, nonblinded study of antiretroviral pharmacokinetics in HIV-infected pregnant women that included 2 cohorts receiving atazanavir/ritonavir 300 mg/100 mg once daily, either with or without tenofovir. Intensive steady-state 24-hour pharmacokinetic profiles were performed during the third trimester and at 6-12 weeks postpartum. Atazanavir was measured by reverse-phase high-performance liquid chromatography (detection limit 0.047 mcg/mL). Pharmacokinetic targets were the estimated 10th percentile atazanavir area under the concentration versus time curve [(AUC): 29.4 mcg · hr · mL-1] in nonpregnant historical controls (mean AUC = 57 mcg · hr · mL-1) and a trough concentration of 0.15 mcg/mL, the concentration target used in therapeutic drug monitoring programs. Median atazanavir AUC was reduced during the third trimester compared with postpartum for subjects not receiving tenofovir (41.9 vs. 57.9 mcg · hr · mL-1, P = 0.02) and for subjects receiving tenofovir (28.8 vs. 39.6 mcg · hr · mL-1, P = 0.04). During the third trimester, AUC was below the target in 33% (6 of 18) of women not receiving tenofovir and 55% (11 of 20) of women receiving tenofovir. Trough concentration was below the target in 6% (1 of 18) of women not receiving tenofovir and 15% (3 of 20) of women receiving tenofovir. The median (range) ratio of cord blood/maternal atazanavir concentration in 29-paired samples was 0.18 (0-0.45). Atazanavir exposure is reduced by pregnancy and by concomitant tenofovir use. A dose increase of atazanavir/ritonavir to 400 mg/100 mg may be necessary in pregnant women to ensure atazanavir exposure equivalent to that seen in nonpregnant adults.
    JAIDS Journal of Acquired Immune Deficiency Syndromes 04/2011; 56(5):412-9. DOI:10.1097/QAI.0b013e31820fd093 · 4.56 Impact Factor
Show more